Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic antifungal agents.

W Abuhammour1, E Habte-Gabr

  • 1Department of Pediatrics, Hurley Medical Centre, Michigan State University-College of Human Medicine, Flint, Michigan, USA. wabuham1@hurleymc.com

Indian Journal of Pediatrics
|August 25, 2001
PubMed
Summary

Systematic antifungal agents like amphotericin B and azoles are crucial for treating fungal infections. Newer formulations of amphotericin B reduce kidney toxicity, while triazoles are preferred for systemic therapy due to fewer side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factitious HIV syndrome in young women.

The AIDS reader·2002
Same author

Cutaneous sporotrichosis: the old iodide treatment remains effective.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2001
Same author

Pulmonary infections in the adolescent with immunodeficiency.

Adolescent medicine (Philadelphia, Pa.)·2000
Same author

Index of suspicion. Case #2. Diagnosis: Anemia from hookworm infestation.

Pediatrics in review·2000
Same author

Nasopharyngeal colonization with Streptococcus pneumoniae in children receiving trimethoprim-sulfamethoxazole prophylaxis.

The Pediatric infectious disease journal·1999
Same author

Picture of the month. Petechial eruption with parvovirus B19 infection.

Archives of pediatrics & adolescent medicine·1999

Area of Science:

  • Pharmacology
  • Mycology
  • Infectious Diseases

Background:

  • Systematic antifungal agents are vital for managing invasive fungal infections.
  • Amphotericin B, discovered in 1955, remains a primary treatment despite resistance in some fungi.
  • Newer liposomal amphotericin B formulations offer reduced nephrotoxicity.

Purpose of the Study:

  • To review systematic antifungal agents.
  • To discuss the properties and applications of amphotericin B, azoles, flucytosine, and griseofulvin.
  • To highlight advancements in antifungal drug development.

Main Methods:

  • Literature review of systematic antifungal agents.
  • Classification of antifungals into major groups.
  • Discussion of drug mechanisms, spectrum of activity, and clinical uses.

Main Results:

  • Amphotericin B is effective against most fungi but has resistance issues with certain species.
  • Azoles are divided into imidazoles (superficial mycoses) and triazoles (systemic therapy).
  • Flucytosine is used adjunctively, and griseofulvin treats dermatophyte infections.

Conclusions:

  • Systematic antifungal agents encompass a range of drugs with distinct applications and resistance profiles.
  • Advancements in drug formulation, such as liposomal amphotericin B, improve safety.
  • Appropriate selection of antifungals is crucial for effective treatment of various mycoses.

Related Experiment Videos